Research programme: psychiatric disorder therapeutics - Ex Scientia/Sunovion Pharmaceuticals
Latest Information Update: 06 Nov 2014
At a glance
- Originator Ex Scientia; Sunovion Pharmaceuticals
- Class Small molecules
- Mechanism of Action G protein-coupled receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Psychiatric disorders
Most Recent Events
- 03 Nov 2014 Early research in Psychiatric disorders in United Kingdom (unspecified route)